Free Newsletter
Reactivated p53 gene plays role in fighting tumors
A team of researchers at MIT, Harvard Medical School and the Howard Hughes Medical Institute have successfully reactivated the tumor suppressing gene p53, dramatically reducing and in some cases eliminating tumors in mice. And if a drug that reactivates p53 can be developed, they say, it could play a major role in fighting cancer. P53 mutations are involved in up to half of all cancer tumors. Several compounds have been identified that can switch the gene back on, but this new research provides compelling data that this approach could make a major impact on the disease. Under normal circumstances, p53 regulates a cell's ability to repair itself or destruct if it can't be fixed. The study used mice engineered so that the p53 gene was turned off. The scientists then reactivated the gene after tumors appeared.
- read the report on the p53 research from MIT
Related Articles:
MIT researchers develop tiny tumor sensor. Report
Nanoparticles used to destroy tumors. Report
Agent prevents tumors from developing in bones. Report
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact




